Oncologists Need to Rely Upon NPs, PAs, and NPPs to Overcome Workforce Problems

News
Video

Eric P. Winer, MD, said, “[Health care] has a workforce problem, which is part of the reason why we need to embrace nurse practitioners and PAs or APPs.”

There is a workforce problem in health care and cancer care specifically. This is precisely why Eric P. Winer, MD, believes the system needs to embrace and incorporate nurse practitioners (NPs), physician assistants (PAs), and advanced practice providers (APPs) into the care model.

Regarding this problem in the workforce, Winer mentioned that 23% of oncologists are 64 years or older and nearing retirement age whereas only 14% of oncologists are younger than 40 years. These numbers came from a snapshot of the oncology workforce published in the Journal of Clinical Oncology. Though these numbers may not directly reflect what changes may happen to the workforce, Winer reiterated that the workforce still needs to expand.

One of the major reasons for this, according to him, is that as treatment has become more advanced and improved survival outcomes, patients have started to live longer and require treatment for longer durations of time.

Compared with when Winer was a younger breast cancer physician and there were far fewer options for treatment, the available resources now make it so patients with active cancer can live for anywhere from 5 to 20 years.

Winer is the director of Yale Cancer Center, president and physician in chief at Smilow Cancer Hospital, deputy dean for cancer research and Alfred Gilman Professor of Pharmacology and Professor of Medicine at Yale School of Medicine, chair of the association board for the American Society of Clinical Oncology, and one of the authors on the survey.

Transcript:

We have a workforce problem, which is part of the reason why we need to embrace [NPs] and PAs or APPs. We need to incorporate them into the care model. There are more oncologists who are nearing retirement age; I’m told, based on ASCO [American Society of Clinical Oncology] work, that 23% of oncologists say they’re nearing retirement age whereas only 14% are under the age of 40. I don’t know that those 2 groups are equal, so there may be people in their late 50s who are going to work for another decade who say they’re nearing retirement age. We are concerned about the fact that, if anything, the oncology workforce needs to expand, because people are living longer with active cancer and they need care—there’s that much more we can do for people. There’s not necessarily an increase in the number of people going into oncology.

When I was a young breast cancer doctor, we didn’t have a lot of treatments. No. 1, everything was much simpler because there were only a few choices, and No. 2, because we only had a few choices, people didn’t live as long when they had incurable cancer. Now there are people who live for 5, 10, 15, and 20 years with active cancer. Our practices get filled up, not by new patients but by all the people who need care and whom we’re taking care of.

References

2023 snapshot: state of the oncology workforce in America. JCO Oncol Pract. 2025;21(3):438. doi:10.1200/OP.24.00262

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Related Content